DE60017888D1 - Dinatrium-salze, monohydrate und ethanol-solvate - Google Patents

Dinatrium-salze, monohydrate und ethanol-solvate

Info

Publication number
DE60017888D1
DE60017888D1 DE60017888T DE60017888T DE60017888D1 DE 60017888 D1 DE60017888 D1 DE 60017888D1 DE 60017888 T DE60017888 T DE 60017888T DE 60017888 T DE60017888 T DE 60017888T DE 60017888 D1 DE60017888 D1 DE 60017888D1
Authority
DE
Germany
Prior art keywords
ethanol solvate
delivery agents
disodium salt
ethanol
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017888T
Other languages
English (en)
Other versions
DE60017888T2 (de
Inventor
E Bay
K Agarwal
Kiran Chaudhary
Shingai Majuru
M Goldberg
P Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Application granted granted Critical
Publication of DE60017888D1 publication Critical patent/DE60017888D1/de
Publication of DE60017888T2 publication Critical patent/DE60017888T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
DE60017888T 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate Expired - Lifetime DE60017888T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12775499P 1999-04-05 1999-04-05
US127754P 1999-04-05
US18614200P 2000-03-01 2000-03-01
US18614300P 2000-03-01 2000-03-01
US186142P 2000-03-01
US186143P 2000-03-01
US19128600P 2000-03-21 2000-03-21
US191286P 2000-03-21
PCT/US2000/009390 WO2000059863A1 (en) 1999-04-05 2000-04-05 Disodium salts, monohydrates, and ethanol solvates

Publications (2)

Publication Number Publication Date
DE60017888D1 true DE60017888D1 (de) 2005-03-10
DE60017888T2 DE60017888T2 (de) 2006-01-19

Family

ID=27494697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017888T Expired - Lifetime DE60017888T2 (de) 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate

Country Status (12)

Country Link
US (6) US20020065255A1 (de)
EP (1) EP1175390B1 (de)
JP (2) JP4588221B2 (de)
AT (1) ATE288415T1 (de)
AU (1) AU4216700A (de)
CA (1) CA2369591C (de)
DE (1) DE60017888T2 (de)
ES (1) ES2235854T3 (de)
HK (1) HK1045680A1 (de)
IL (4) IL145546A0 (de)
NZ (1) NZ534409A (de)
WO (1) WO2000059863A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
JP4675481B2 (ja) 1998-07-27 2011-04-20 エミスフェアー・テクノロジーズ・インク 活性剤の肺性デリバリー
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
WO2001051454A1 (en) * 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20040186050A1 (en) 2001-06-01 2004-09-23 Ault Joseph M Method for orally administering parathyroid hormone (pth)
KR20040030120A (ko) 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
AU2003223158B2 (en) 2002-01-09 2008-01-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PL1651249T3 (pl) 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
MXPA06001916A (es) 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005115406A2 (en) 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
CN1953753B (zh) * 2004-05-06 2011-02-09 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
KR101193228B1 (ko) * 2004-05-06 2012-10-22 에미스페어 테크놀로지스, 인코포레이티드 모노소듐 ｎ-［8-(2-히드록시벤조일)아미노］카프릴레이트의 결정 다형 형태
CN102040537A (zh) 2004-05-06 2011-05-04 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
RU2006138703A (ru) 2004-05-06 2008-06-20 Эмисфире Текнолоджис Твердая лекарственная форма увлажненного гепарина
MXPA06013252A (es) 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
BRPI0510221A (pt) 2004-05-14 2007-10-23 Emisphere Tech Inc composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
RU2530889C2 (ru) * 2004-05-14 2014-10-20 Эмисфире Текнолоджис, Инк. Соединения и составы для доставки активных веществ
AU2005244986B2 (en) * 2004-05-19 2011-01-27 Emisphere Technologies, Inc. Topical cromolyn formulations
WO2005112937A1 (en) * 2004-05-19 2005-12-01 Emisphere Technologies, Inc. Acyclovir formulations
EP1791553B1 (de) * 2004-07-12 2013-10-23 Emisphere Technologies, Inc. Zusammensetzungen zur abgabe von peptid yy und pyy agonisten
US20100048454A1 (en) 2004-08-03 2010-02-25 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AU2005321803B2 (en) * 2004-12-29 2012-02-09 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
TWI386386B (zh) * 2005-09-19 2013-02-21 Emisphere Tech Inc Ｎ-（５-氯柳醯基）-８-胺基辛酸之二鈉鹽的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CA2662853C (en) 2006-08-31 2016-07-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2008027854A2 (en) 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
CA2662080C (en) * 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
AU2008223108B2 (en) * 2007-03-02 2013-10-10 Novartis Ag Oral administration of a calcitonin
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
ES2622281T3 (es) 2007-08-09 2017-07-06 Novartis Ag Composiciones orales de calcitonina y sus aplicaciones
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
EP2331522B1 (de) * 2008-08-01 2013-09-18 Purdue Pharma LP Tetrahydropyridinyl- und dihydropyrrolylverbindungen und ihre verwendung
ES2626327T3 (es) 2009-02-06 2017-07-24 The Regents Of The University Of California Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
CN102369018B (zh) * 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
EP2538945A4 (de) * 2010-02-24 2013-07-24 Emisphere Tech Inc Orale b12-therapie
EA026713B1 (ru) * 2010-06-09 2017-05-31 Эмисфире Текнолоджис, Инк. Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
ES2678145T3 (es) 2010-08-24 2018-08-09 Abbott Laboratories Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
ES2645769T3 (es) 2011-01-05 2017-12-07 Hospira, Inc. Secado por pulverización de la vancomicina
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
TR201808456T4 (tr) 2011-11-02 2018-07-23 Keybioscience Ag Hastalıklar ve rahatsızlıkların tedavi edilmesine yönelik kalsitonin mimetikleri.
CN103998052B (zh) * 2011-11-02 2016-08-17 关键生物科学有限公司 用于治疗疾病和紊乱的肽类似物
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
EP2884971A4 (de) 2012-08-16 2016-01-06 Ohio State Innovation Foundation Stat3-inhibitoren und ihre verwendung gegen krebs
EP2890370B1 (de) 2012-08-31 2019-10-09 The Regents of the University of California Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
SG11201501850VA (en) 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP6462681B2 (ja) 2013-07-12 2019-01-30 ジェネンテック， インコーポレイテッド イオン交換クロマトグラフィーのインプットの最適化の解明
PT3321278T (pt) 2013-11-14 2019-03-19 Keybioscience Ag Miméticas de calcitonina para tratar doenças e distúrbios
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
JP6925970B2 (ja) * 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 副甲状腺機能低下症の治療
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
JP6983868B2 (ja) 2016-04-22 2021-12-17 レセプター・ホールディングス・インコーポレイテッド 即効性の植物由来医薬化合物及び栄養補給剤
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US11186622B2 (en) 2017-01-05 2021-11-30 The Regents Of The University Of California PAC1 receptor agonists (MAXCAPS) and uses thereof
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
CN111225678A (zh) * 2017-10-05 2020-06-02 受体控股公司 快速起效且延长作用的植物类及合成大麻素制剂
AR113750A1 (es) * 2017-10-05 2020-06-10 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
EP3773475A1 (de) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmazeutische zusammensetzungen zur transmukosalen abgabe von therapeutischen peptiden und proteinen
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN111057165A (zh) * 2020-01-13 2020-04-24 苏州健飞肠衣有限公司 一种高纯度肝素钠的制备方法
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
EP4323330A1 (de) 2021-04-16 2024-02-21 Navinta III Inc Verfahren zur herstellung von hochreiner salcaprozinsäure und pharmazeutisch akzeptablen salzen daraus
BR112023021766A2 (pt) 2021-04-22 2024-01-23 Civi Biopharma Inc Dispensação oral de oligonucleotídeo
KR20240035495A (ko) 2021-07-16 2024-03-15 노보 노르디스크 에이/에스 나트륨 n-(8-(2-하이드록시벤조일)아미노)카프릴레이트 다형체 형태 a
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES369853A1 (es) * 1969-07-24 1971-07-16 Bama S A Lab Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DE2532420A1 (de) * 1975-07-19 1977-02-03 Boehringer Mannheim Gmbh Phenylessigsaeure-derivate und verfahren zu ihrer herstellung
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) * 1980-11-09 1984-04-10 Kyoto Yakuhin Kogyo Kabushiki Kaisha Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
GB2092136B (en) * 1981-01-17 1985-06-05 Mitsui Toatsu Chemicals Production of n-substituted amide compounds
JPS58140026A (ja) * 1982-01-14 1983-08-19 Toyo Jozo Co Ltd 吸収性良好な製剤
CA1188987A (en) 1981-03-06 1985-06-18 Masataka Morishita Preparation having excellent absorption property
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4393192A (en) * 1982-12-21 1983-07-12 The Standard Oil Company Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4689182A (en) 1985-12-20 1987-08-25 Warner-Lambert Company Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPH0725725B2 (ja) * 1987-07-23 1995-03-22 保土谷化学工業株式会社 ベンズアミド誘導体
FR2636238B1 (fr) * 1988-09-14 1994-01-21 Morelle Jean Nouvelles compositions antisudorales
GB8823731D0 (en) 1988-10-10 1988-11-16 Smith Kline French Lab Biologically active compounds
FR2639395B1 (fr) 1988-11-18 1991-02-15 Rockwell Cim Dispositif d'accouplement entre une vitre et un mecanisme de leve-vitre a bras oscillants dans un vehicule automobile
JPH02239980A (ja) 1989-03-15 1990-09-21 Fuji Photo Film Co Ltd 感熱記録材料
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
HU211995B (en) * 1992-06-30 1996-01-29 Gyogyszerkutato Intezet Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
EP1025840B1 (de) * 1993-04-22 2005-06-29 Emisphere Technologies, Inc. Orale Dareichungsform
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
IL126318A (en) * 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
GB2314189B (en) 1996-06-14 2000-08-09 Mars Inc Coin handling apparatus
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6051561A (en) * 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
PT1093819E (pt) * 1997-02-07 2006-09-29 Emisphere Tech Inc Compostos e composicoes para fornecimento de agentes activos
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CO5021171A1 (es) * 1997-12-08 2001-03-27 Smithkline Beechman Corp Sal de monoargininilo del acido(e)-3-(1-n-butil-5-(2-(2- carboxifenil)metoxi-4-clorofenil)-1h-pirazol-4-il)-2- ((5-metoxi-2,3-dihidrobenzofuran-5-il)metil)-prop-2-enoico
JP4675481B2 (ja) 1998-07-27 2011-04-20 エミスフェアー・テクノロジーズ・インク 活性剤の肺性デリバリー
HUP0103188A2 (hu) 1998-08-07 2001-12-28 Emisphere Technologies, Inc. Vegyületek és készítmények hatóanyagok célbajuttatására
US6066015A (en) 1998-08-17 2000-05-23 Brown; James D. Method and system for anchoring a buoy via a screw-type anchor
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CN103212071B (zh) 2005-08-25 2017-12-12 亚利桑那大学董事会 干细胞融合癌发生模型
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation
WO2011048589A2 (en) 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof

Also Published As

Publication number Publication date
EP1175390A1 (de) 2002-01-30
IL180118A (en) 2010-12-30
US8658695B2 (en) 2014-02-25
US20040106825A1 (en) 2004-06-03
IL145546A0 (en) 2002-06-30
NZ534409A (en) 2006-03-31
US20120264834A1 (en) 2012-10-18
ES2235854T3 (es) 2005-07-16
EP1175390B1 (de) 2005-02-02
DE60017888T2 (de) 2006-01-19
US7384982B2 (en) 2008-06-10
JP2005068161A (ja) 2005-03-17
CA2369591A1 (en) 2000-10-12
US7659311B2 (en) 2010-02-09
AU4216700A (en) 2000-10-23
HK1045680A1 (en) 2002-12-06
US8003697B2 (en) 2011-08-23
US20110251125A1 (en) 2011-10-13
JP4588221B2 (ja) 2010-11-24
CA2369591C (en) 2011-06-14
IL145546A (en) 2007-10-31
JP4642435B2 (ja) 2011-03-02
IL180118A0 (en) 2007-06-03
US20100099621A1 (en) 2010-04-22
ATE288415T1 (de) 2005-02-15
EP1175390A4 (de) 2002-09-04
US20080269134A1 (en) 2008-10-30
JP2002541132A (ja) 2002-12-03
IL166158A0 (en) 2006-01-15
US8207227B2 (en) 2012-06-26
WO2000059863A1 (en) 2000-10-12
IL166158A (en) 2010-12-30
US20020065255A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
DE60017888D1 (de) Dinatrium-salze, monohydrate und ethanol-solvate
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DE60031999D1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
HUP0103318A2 (hu) Eljárás hatóanyagok bevitelére tüdőn keresztül
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
RU2008123380A (ru) Фармацевтическая композиция
HUP0401441A2 (hu) Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere
AR013157A1 (es) Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
RU2005105691A (ru) Пероральное введение кальцитонина
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
MY129537A (en) Amino acid ester containing azole antifungals
JP2006524182A5 (de)
UY26365A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberación de agentes activos
TH51556B (th) เกลือไดโซเดียม โมโนไฮเดรต และเอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
AR036219A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberacion de agentes activos
TH51556A (th) เกลือไดโซเดียม โมโนไฮเดรต และ เอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EMISPHERE TECHNOLOGIES, INC., CEDAR KNOLLS, N., US